Real-world research of vonoprazan and amoxicillin dual therapy for Helicobacter pylori eradication
- VernacularTitle:伏诺拉生与阿莫西林二联方案根除幽门螺杆菌的真实世界研究
- Author:
Yuanlong HUANG
1
;
Houdong ZUO
2
,
3
;
Benhong MAO
1
;
Wei ZHAO
1
;
Ying ZHANG
1
;
Yaxiong LI
1
;
Yin YING
1
;
Lu GAN
1
Author Information
1. Dept. of Gastroenterology，Chengdu Xinhua Hospital，Chengdu 610067，China
2. Dept. of Radiology，Chengdu Xinhua Hospital，Chengdu 610067，China
3. Dept. of Radiology，the Affiliated Hospital of North Sichuan Medical College/Sichuan Key Laboratory of Medical Imaging，Sichuan Nanchong 637000，China
- Publication Type:Journal Article
- Keywords:
vonoprazan;
amoxicillin;
Helicobacter pylori;
bismuth-containing quadruple therapy;
efficacy;
safety;
cost
- From:
China Pharmacy
2023;34(22):2775-2779
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the efficacy， safety and economics of a dual therapy consisting of conventional dose of vonoprazan combined with conventional dose of amoxicillin in patients with primary treatment of Helicobacter pylori （HP） infection. METHODS Using a prospective cohort study， the patients diagnosed with HP infection and receiving initial treatment in Chengdu Xinhua Hospital from July 2021 to July 2022 were collected according to inclusion and exclusion criteria. The patients were given vonoprazan/amoxicillin dual therapy （i.e. VA group， Vonoprazan fumarate tablets 20 mg， once a day+Amoxicillin capsules 1.0 g， twice a day， 14 days） and bismuth-containing quadruple therapy （i.e. LJAF group， Rabeprazole sodium enteric- coated tablets 20 mg， twice a day+Colloidal bismuth pectin capsules 200 mg， twice a day+Amoxicillin capsules 1.0 g， twice a day+ Furazolidone tablets 100 mg， twice a day， for 14 days） according to the patient’s medication willingness. Four weeks after the end of the treatment， HP eradication rates of the two groups were compared by using intention-to-treat （ITT）， modified intention-to- treat （MITT） and per-protocol （PP） analysis. The occurrence of adverse drug reactions （ADR） was recorded， and an economic evaluation was performed for them. RESULTS Among the 58 patients in VA group， 55 completed the trial， 2 were lost to follow- up and one withdrew due to rash； among the 62 patients in LJAF group， 57 completed the trial， 3 were lost to follow-up and 2 withdrew due to rash. Results of ITT， MITT and PP analysis showed that HP eradication rates of VA group were 86.2%， 89.3% and 90.9%， and those of LJAF group were 87.1%，91.5% and 94.7%， respectively； there was no statistical significance among different groups （P＞0.05）. The incidences of ADR in VA group and LJAF group were 6.9% and 14.5%，which were not significantly different （P＞0.05）. The result of cost minimization analysis showed that the treatment cost of VA group was 340.9 yuan， which was lower than 373.5 yuan of LJAF group. CONCLUSIONS In patients with primary treatment of HP infection， the efficacy and safety of dual therapy of conventional dose of vonoprazan combined with conventional dose of amoxicillin is equivalent to the bismuth-containing quadruplex therapy with low cost.
